In 2012, Inovalon partnered with industry researchers to conduct a study on
Hospital Readmission Rates in Medicare Advantage Plans to track readmission rates among patients enrolled in Medicare’s private comprehensive Medicare Advantage plans, and develop initial comparisons with fee-for-service (FFS) readmission rates. The study was published in
The American Journal of Managed Care. In 2013, Inovalon partnered with
Walgreens and
electronic health record (EHR) companies such as
Allscripts, Greenway, and NeoDeck to integrate analytics platforms into the point of care. Inovalon also examined the association of socioeconomic status and other factors with underlying poor quality performance of dual-eligible members in Medicare Advantage plans, releasing a study on October 28, 2014 that was presented to Congressional representatives on October 21, 2014. In 2014, Inovalon expanded its partnership with Walgreens to implement its "ePASS" patient assessment tool and technology platform in clinics at Walgreens locations. In May 2015, Inovalon released an analysis of dual eligible member data, which indicated that social and demographic factors affect health-related outcomes and measurements for health plan performance, independent of plan characteristics. On September 1, 2015, Inovalon acquired
Avalere Health, a strategic advisory company providing solutions to the pharmaceutical industry, managed care companies and provider organizations for $140 Million. The addition of Avalere, which serves 13 of the top 15 pharmaceutical companies has enabled Inovalon to expand its capabilities into an expansive adjacent market. In September 2016, Inovalon announced the acquisition of Creehan Holding Co., Inc., the parent company of Creehan & Company, a provider of specialty pharmacy and specialty medications management software-as-a-service platforms. The acquisition closed on October 1, 2016. In January 2017, Inovalon announced a partnership with
Boehringer Ingelheim Pharmaceuticals Inc. on behalf of Boehringer Ingelheim’s diabetes alliance with
Eli Lilly and Company, to support outcomes-based contracting and improve patient care. On September 12, 2017, Inovalon announced UnitedHealthcare had entered into an agreement to implement the Inovalon ONE™ platform. Later that month, Inovalon announced a partnership with
Daiichi Sankyo, Inc. to help develop outcomes-based contracts addressing opioid pain management. In March 2018, Inovalon announced the acquisition of Minneapolis-based ABILITY Network, a cloud-based Software-as-a-Service (SaaS) healthcare technology company, for $1.2 billion. The acquisition closed on April 2, 2018. In June 2018, Inovalon announced a five-year engagement with AllianceRx Walgreens Prime, the combined central specialty and home delivery pharmacy formed by Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), to bring technology advancements to the specialty pharmacy marketplace. In June 2020, Inovalon announced a five-year engagement with Cardinal Health, Inc., to provide a configuration of Inovalon’s ScriptMed® Cloud. The platform will be used to support Cardinal Health's durable medical equipment and medical supplies business. In July 2020, Inovalon announced an engagement with Walmart’s Specialty Pharmacy business to provide cloud-based capabilities through the Inovalon ONE® Platform to support improved outcomes and economics for its customers. == References ==